Article

Graphene Coating Boosts Chemotherapy Drug Effectiveness

Author(s):

Silver is a useful element to prevent bacterial growth.

Silver is a useful element to prevent bacterial growth.

Researchers have found a solution after learning that silver coating on catheter equipment can break down the effectiveness of chemotherapy drugs.

Silver is a useful element to prevent bacterial growth. This is critical for patients receiving intravenous (IV) medication with compromised immune systems, like those on chemotherapy.

A physics research team at Norweigan University of Science and Technology (NTNU) used x-ray photoemission spectroscopy (XPS) to look at a common chemotherapy drug, 5-Fluorouracil (5-Fu), and found that not only does silver reduce chemotherapy drug effectiveness, but it also emits a harmful gas, hydrogen fluoride.

To fix this problem, the team at NTNU tested to see how the same chemotherapy drugs would react with a different metal, graphene. Graphene, sometimes called a "magical material," did not react with chemotherapy drugs and boosted chemotherapy's effects.

"This research has produced valuable information about the interaction between chemotherapy drugs and other substances that the medicine is in contact with,” said Justin Wells, an associate professor of physics at NTNU. “We hope that our work will contribute to making cancer treatment more effective, and that we can continue our work in this area. We would like to study the reaction between chemotherapy drugs and other substances and coatings used on medical equipment.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards